Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study

Published:November 24, 2022DOI:



      Investigate the effectiveness of IDegLira, a fixed-ratio combination of insulin degludec/liraglutide, in a real-world setting in patients with type 2 diabetes mellitus in the United Arab Emirates.


      This non‐interventional study enrolled adults switching to IDegLira from basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with/without concomitant oral antidiabetic drugs (OADs). Primary endpoint was change in HbA1c from baseline, assessed using a mixed model for repeated measurements.


      Among 263 patients (BI ± OADs, n=206; GLP-1 RA ± OADs, n=57), mean baseline HbA1c was 9.29% (78 mmol/mol). After 26 weeks, HbA1c was significantly reduced (BI ± OADs, –0.83% [–9.0 mmol/mol] and GLP-1 RA ± OADs, –1.24% [–13.5 mmol/mol]; both p<0.0001). Fasting plasma glucose (FPG) was significantly reduced (–39.48 mg/dL [BI ± OADs] and –82.49 mg/dL [GLP-1 RA ± OADs]; both p<0.0001). Before treatment initiation, 3/263 patients experienced ≥1 severe hypoglycaemic episode and 7/263 patients experienced ≥1 non-severe hypoglycaemic episode compared with 1/263 patients who had ≥1 severe and 1/263 who had ≥1 non-severe episode at end of study. Body weight decreased significantly among patients switching from BI ± OADs (–1.05 kg [p<0.0001]). Treatment was well tolerated.


      IDegLira significantly reduced HbA1c and FPG in this real-world setting, along with less frequent episodes of hypoglycaemia. Switching to IDegLira offers effective treatment intensification for type 2 diabetes patients with inadequate glycaemic control.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Harris Stewart
        • Abrahamson Martin J.
        • Ceriello Antonio
        • Charpentier Guillaume
        • Evans Marc
        • Lehmann Roger
        • et al.
        Clinical considerations when initiating and titrating insulin degludec/liraglutide (IDegLira) in people with type 2 diabetes.
        Drugs. 2020; 80: 147-165
        • Ostawal A.
        • Mocevic E.
        • Kragh N.
        • Xu W.
        Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review.
        Diabetes Ther. 2016; 7: 411-438
      1. American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl 1):S73–S84. doi: 10.2337/dc21-S006.

        • Holman R.R.
        • Paul S.K.
        • Bethel M.A.
        • Matthews D.R.
        • Neil H.A.
        10-year follow-up of intensive glucose control in type 2 diabetes.
        N Engl J Med. 2008; 359: 1577-1589
        • Moreira Rodrigo Oliveira
        • Cobas Roberta
        • Lopes Assis Coelho Raquel C.
        Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?.
        Diabetol Metab Syndr. 2018; 10
        • Hughes E.
        IDegLira: redefining insulin optimisation using a single injection in patients with type 2 diabetes.
        Prim Care Diabetes. 2016; 10: 202-209
      2. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018;41(12):2669–701. doi: 10.2337/dci18-0033.

      3. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 2021;44(Suppl 1):S111–S24. doi: 10.2337/dc21-S009.

        • Alawadi Fatheya
        • Alsaeed Maryam
        • Bachet Fawzi
        • Bashier Alaaeldin
        • Abdulla Khadija
        • Abuelkheir Sona
        • et al.
        Impact of provision of optimum diabetes care on the safety of fasting in Ramadan in adult and adolescent patients with type 1 diabetes mellitus.
        Diabetes Res Clin Pract. 2020; 169: 108466
        • Fadini G.P.
        • Disoteo O.
        • Candido R.
        • Di Bartolo P.
        • Laviola L.
        • Consoli A.
        Delphi-based consensus on treatment intensification in type 2 diabetes subjects failing basal insulin supported oral treatment: focus on basal insulin + GLP-1 receptor agonist combination therapies.
        Diabetes Ther. 2021; 12: 781-800
        • Vedtofte L.
        • Knop F.K.
        • Vilsboll T.
        Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.
        Expert Opin Drug Saf. 2017; 16: 387-396
        • Greig S.L.
        • Scott L.J.
        Insulin degludec/liraglutide: a review in type 2 diabetes.
        Drugs. 2015; 75: 1523-1534
        • Gough Stephen C L
        • Bode Bruce
        • Woo Vincent
        • Rodbard Helena W
        • Linjawi Sultan
        • Poulsen Pernille
        • et al.
        Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
        Lancet Diabetes Endocrinol. 2014; 2: 885-893
      4. Xultophy. [prescribing information]. 2019. [accessed 15 December 2021].

      5. Xultophy. [summary of product characteristics]. 2020. [accessed 15 December 2021].

        • Buse J.B.
        • Vilsboll T.
        • Thurman J.
        • Blevins T.C.
        • Langbakke I.H.
        • Bottcher S.G.
        • et al.
        Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).
        Diabetes Care. 2014; 37: 2926-2933
        • Lingvay Ildiko
        • Manghi Federico Pérez
        • García-Hernández Pedro
        • Norwood Paul
        • Lehmann Lucine
        • Tarp-Johansen Mads Jeppe
        • et al.
        Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial.
        JAMA. 2016; 315: 898
        • Billings Liana K.
        • Doshi Ankur
        • Gouet Didier
        • Oviedo Alejandra
        • Rodbard Helena W.
        • Tentolouris Nikolaos
        • et al.
        Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial.
        Diabetes Care. 2018; 41: 1009-1016
        • Linjawi Sultan
        • Bode Bruce W.
        • Chaykin Louis B.
        • Courrèges Jean-Pierre
        • Handelsman Yehuda
        • Lehmann Lucine M.
        • et al.
        The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial.
        Diabetes Ther. 2017; 8: 101-114
        • Rodbard H.W.
        • Bode B.W.
        • Harris S.B.
        • Rose L.
        • Lehmann L.
        • Jarlov H.
        • et al.
        Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with type 2 diabetes: the DUAL IV trial.
        Diabet Med. 2017; 34: 189-196
        • Harris Stewart B.
        • Kocsis Győző
        • Prager Rudolf
        • Ridge Terry
        • Chandarana Keval
        • Halladin Natalie
        • et al.
        Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.
        Diabetes Obes Metab. 2017; 19: 858-865
        • Sesti G.
        • Bardtrum L.
        • Dagdelen S.
        • Halladin N.
        • Haluzik M.
        • Orsy P.
        • et al.
        A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
        Diabetes Obes Metab. 2020; 22: 873-878
        • Philis‐Tsimikas Athena
        • Billings Liana K.
        • Busch Robert
        • Portillo Cristobal Morales
        • Sahay Rakesh
        • Halladin Natalie
        • et al.
        Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes.
        Diabetes Obes Metab. 2019; 21: 1399-1408
        • Price H.
        • Bluher M.
        • Prager R.
        • Phan T.M.
        • Thorsted B.L.
        • Schultes B.
        • et al.
        Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: results from a European, multicentre, retrospective chart review study.
        Diabetes Obes Metab. 2018; 20: 954-962
        • Sofra D.
        Glycemic control in a real-life setting in patients with type 2 diabetes treated with IDegLira at a single Swiss center.
        Diabetes Ther. 2017; 8: 377-384
        • Melzer-Cohen C.
        • Chodick G.
        • Naftelberg S.
        • Shehadeh N.
        • Karasik A.
        Metabolic control and adherence to therapy in type 2 diabetes mellitus patients using IDegLira in a real-world setting.
        Diabetes Ther. 2020; 11: 185-196
        • Egede L.E.
        • Bogdanov A.
        • Fischer L.
        • Da Rocha Fernandes J.D.
        • Kallenbach L.
        Glycemic control among patients newly prescribed IDegLira across prior therapy group in US real-world practice.
        Diabetes Ther. 2020; 11: 1579-1589
        • Di Loreto C.
        • Celleno R.
        • Piastrella L.
        • Del Sindaco P.
        IDegLira fixed-ratio combination in the real world: a retrospective observational single-center Italian experience.
        Eur Rev Med Pharmacol Sci. 2020; 24: 10671-10679
        • Eliasson Björn
        • Ekelund Jan
        • Miftaraj Mervete
        • Ranthe Mattis Flyvholm
        • Mårdby Ann-Charlotte
        • Da Rocha Fernandes João Diogo
        • et al.
        Persistence with IDegLira in patients in clinical practice: a nationwide observational study in Sweden.
        Diabetes Ther. 2020; 11: 1807-1820
        • Persano M.
        • Nollino L.
        • Sambataro M.
        • Rigato M.
        • Negro I.
        • Marchetto S.
        • et al.
        Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy.
        Eur Rev Med Pharmacol Sci. 2021; 25: 923-931
        • Zenari Luciano
        • Da Porto Andrea
        • De Moliner Lorena
        • Lugli Francesca
        • Guazzoni Valeria
        • Groppelli Gloria
        • et al.
        Real-World evaluation of glycemic outcomes and extra-glycemic parameters in diabetic patients treated with the combined formulation degludec-liraglutide (IDegLira).
        Diabetes Ther. 2021; 12: 197-209
      6. International Diabetes Federation. IDF Diabetes Atlas, 10th edn 2021. [accessed 4 January 2022].

      7. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 2004. [accessed 10 March 2022].

      8. International Society for Pharmacoepidemiology. Guidelines for Good Pharmacoepidemiology Practices (GPP). 2015. [accessed 10 March 2022].

      9. Alawadi F, Abusnana S, Afandi B, Aldahmani KM, Alhajeri O, Aljaberi K, et al. Emirates Diabetes Society Consensus guidelines for the management of type 2 diabetes mellitus – 2020. Dubai Diabetes Endocrinol J 2020;26(1):1-20. doi: 10.1159/000506508.

        • Deed G.
        • Barlow J.
        • Kuo I.
        Early and tight glycaemic control - the key to managing type 2 diabetes.
        Aust Fam Physician. 2012; 41: 681-684
        • Drummond R.
        • Baru A.
        • Dutkiewicz M.
        • Basse A.
        • Tengmark B.O.
        Physicians' real-world experience with IDegLira: results of a European survey.
        BMJ Open Diabetes Res Care. 2018; 6: e000531
        • Fadini Gian Paolo
        • Feher Michael
        • Hansen Troels Krarup
        • de Valk Harold W
        • Koefoed Mette Marie
        • Wolden Michael
        • et al.
        Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: a prospective study.
        J Clin Endocrinol Metab. 2019; 104: 5977-5990